All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2019-06-17T14:48:10.000Z

EHA 2019 | Results from FORTE trial of KRd in NDMM

By Emily Smith, Francesca Gay
Jun 17, 2019
Share:

Bookmark this article

At the 24th Congress of the European Hematology Association (EHA), Francesca Gay from the University of Torino, IT, talks about impact of the results from the FORTE trial of carfilzomib (K) with lenalidomide (R) and dexamethasone (d) (KRd) in patients with newly diagnosed multiple myeloma (NDMM), on clinical practice.

 
KRd-ASCT-KRd and KRd12 showed superior outcomes, inducing high-quality responses, as well as approximately 50% of patients with high-risk disease achieving minimal residual disease (MRD) negativity. ASCT proved to be beneficial in high-risk patients, reducing the risk of early relapse.

Results from FORTE trial of KRd in NDMM

More about...
CarfilzomibDexamethasoneEHAEHA 2019FORTELenalidomideNewly diagnosed multiple myeloma

Your opinion matters

Which dosing schedule for belantamab mafodotin do you think is optimal for providing an efficacy benefit while managing toxicities?
2 votes - 42 days left ...

Related articles

Add bookmark

EHA 2019 | Novel agents for NDMM: EHA updates

Elena Zamagni from the Bologna University School of Medicine, Italy, gives an EHA update on novel agents for newly diagnosed multiple myeloma (NDMM).

Jun 17, 2019
Add bookmark

EHA 2019 | Novel agents for NDMM: EHA updates

Elena Zamagni from the Bologna University School of Medicine, Italy, gives an EHA update on novel agents for newly diagnosed multiple myeloma (NDMM).

Jun 17, 2019
Add bookmark

ASCO 2019 | Risk subgroup analysis from the FORTE trial

On Sunday 02 June, 2019, Francesca Gay, University of Torino, Torino, IT, presented an updated risk analysis from the FORTE trial (NCT02203643) during the ASCO meeting.

Jun 10, 2019
Add bookmark

ASCO 2019 | Risk subgroup analysis from the FORTE trial

On Sunday 02 June, 2019, Francesca Gay, University of Torino, Torino, IT, presented an updated risk analysis from the FORTE trial (NCT02203643)...

Jun 10, 2019

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox